242 related articles for article (PubMed ID: 31648964)
1. Monosomy of Chromosome 9 Is Associated With Higher Grade, Advanced Stage, and Adverse Outcome in Clear-cell Renal Cell Carcinoma.
Nejati R; Wei S; Uzzo RG; Poureghbali S; Pei J; Talarchek JN; Ruth K; Dulaimi E; Kutikov A; Testa JR; Al-Saleem T
Clin Genitourin Cancer; 2020 Feb; 18(1):56-61. PubMed ID: 31648964
[TBL] [Abstract][Full Text] [Related]
2. Female Gender Predicts Favorable Prognosis in Patients With Non-metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery: Results From the International Marker Consortium for Renal Cancer (INMARC).
Fukushima H; Saito K; Yasuda Y; Tanaka H; Patil D; Cotta BH; Patel SH; Master VA; Derweesh IH; Fujii Y
Clin Genitourin Cancer; 2020 Apr; 18(2):111-116.e1. PubMed ID: 32001181
[TBL] [Abstract][Full Text] [Related]
3. Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.
Fu Q; Liu Z; Pan D; Zhang W; Xu L; Zhu Y; Liu H; Xu J
Cancer Sci; 2014 Nov; 105(11):1427-34. PubMed ID: 25155155
[TBL] [Abstract][Full Text] [Related]
4. FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis.
Zhang Y; Zhu X; Qiao X; Sun L; Tian Y; Yang Y; Zhao Y; Liu C
Int J Med Sci; 2020; 17(17):2819-2825. PubMed ID: 33162809
[No Abstract] [Full Text] [Related]
5. Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery.
El-Mokadem I; Fitzpatrick J; Bondad J; Rauchhaus P; Cunningham J; Pratt N; Fleming S; Nabi G
Br J Cancer; 2014 Sep; 111(7):1381-90. PubMed ID: 25137021
[TBL] [Abstract][Full Text] [Related]
6. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Laba P; Wang J; Zhang J
BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
[TBL] [Abstract][Full Text] [Related]
7. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
[TBL] [Abstract][Full Text] [Related]
8. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 9p deletions are an independent predictor of tumor progression following nephrectomy in patients with localized clear cell renal cell carcinoma.
de Oliveira D; Dall'Oglio MF; Reis ST; Zerati M; Souza IC; Leite KR; Srougi M
Urol Oncol; 2014 Jul; 32(5):601-6. PubMed ID: 24629495
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma.
Shim M; Song C; Park S; Choi SK; Cho YM; Kim CS; Ahn H
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2213-20. PubMed ID: 26215891
[TBL] [Abstract][Full Text] [Related]
11. Elevated Expression of N-Acetylgalactosaminyltransferase 10 Predicts Poor Survival and Early Recurrence of Patients with Clear-Cell Renal Cell Carcinoma.
Wu Q; Yang L; Liu H; Zhang W; Le X; Xu J
Ann Surg Oncol; 2015 Jul; 22(7):2446-53. PubMed ID: 25391266
[TBL] [Abstract][Full Text] [Related]
12. Tumor volume: a new prognostic factor of oncological outcome of localized clear cell renal cell carcinoma.
Chen SH; Xu LY; Wu YP; Ke ZB; Huang P; Lin F; Li XD; Xue XY; Wei Y; Zheng QS; Xu N
BMC Cancer; 2021 Jan; 21(1):79. PubMed ID: 33468079
[TBL] [Abstract][Full Text] [Related]
13. β1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.
Liu Y; Liu H; Liu W; Zhang W; An H; Xu J
World J Urol; 2015 Nov; 33(11):1791-9. PubMed ID: 25630622
[TBL] [Abstract][Full Text] [Related]
14. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma.
An H; Xu L; Chang Y; Zhu Y; Yang Y; Chen L; Lin Z; Xu J
Eur J Cancer; 2015 Sep; 51(14):1953-61. PubMed ID: 26188847
[TBL] [Abstract][Full Text] [Related]
15. The miR-200 family as prognostic markers in clear cell renal cell carcinoma.
Saleeb R; Kim SS; Ding Q; Scorilas A; Lin S; Khella HW; Boulos C; Ibrahim G; Yousef GM
Urol Oncol; 2019 Dec; 37(12):955-963. PubMed ID: 31635993
[TBL] [Abstract][Full Text] [Related]
16. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
[TBL] [Abstract][Full Text] [Related]
17. IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma.
Bai Q; Liu L; Xia Y; Wang J; Xi W; Qu Y; Xiong Y; Long Q; Xu J; Guo J
Oncotarget; 2017 Jul; 8(27):44186-44194. PubMed ID: 28562332
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of renin is a prognostic factor for recurrence in nonmetastatic renal cell carcinoma.
de Almeida E Paula F; Bezerra SM; da Cunha IW; Munhoz GC; Abreu D; Lara PN; da Costa WH; Zéqui SC
Urol Oncol; 2019 Dec; 37(12):947-954. PubMed ID: 31473089
[TBL] [Abstract][Full Text] [Related]
19. Histologic prognostic factors associated with chromosomal imbalances in a contemporary series of 89 clear cell renal cell carcinomas.
Dagher J; Dugay F; Verhoest G; Cabillic F; Jaillard S; Henry C; Arlot-Bonnemains Y; Bensalah K; Oger E; Vigneau C; Rioux-Leclercq N; Belaud-Rotureau MA
Hum Pathol; 2013 Oct; 44(10):2106-15. PubMed ID: 23806527
[TBL] [Abstract][Full Text] [Related]
20. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
